Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| CAMA-1 | Cisplatin | Chemo | Chemotherapy | 0.91281 | -0.0042 | 0.3350 | 0.0351 | 0.4780 | 9.0889 | 0.95264 |
| CAMA-1 | Doxorubicin | Chemo | Chemotherapy | 0.0074655 | -0.6517 | 0.8426 | 0.2593 | 0.7583 | 0.020458 | 0.96039 |
| CAMA-1 | Taxol | Chemo | Chemotherapy | 0.0022699 | -0.4944 | 0.9525 | 0.3547 | 2.4920 | 0.0029769 | 0.99478 |
| CAMA-1 | Topotecan | Topo I | Chemotherapy | 0.0032129 | -0.4230 | 1.0539 | 0.2099 | 1.1100 | 0.0049245 | 0.96968 |
| CAMA-1 | Etoposide | Topo II | Chemotherapy | 0.15466 | -0.4476 | 0.5722 | 0.1479 | 1.3512 | 0.24426 | 0.99498 |
| CAMA-1 | Dasatinib | BCR/ABL | MAPK/nRTK | Inf | 0.6790 | 0.1521 | -0.0025 | 0.1987 | 999.7954 | 0.90943 |
| CAMA-1 | Trametinib | MEK | MAPK/nRTK | 4.9546 | 0.5526 | 0.1688 | 0.0031 | 0.5322 | 0.09227 | 0.9741 |
| CAMA-1 | Saracatinib | SRC | MAPK/nRTK | Inf | 0.7736 | 0.0306 | -0.0005 | 1.1372 | 11.0154 | 0.85387 |
| CAMA-1 | ABT-737 | Bcl2/XL | Misc | Inf | 0.8643 | 0.0008 | 0.0221 | 5.0000 | 3.6752 | 0.74188 |
| CAMA-1 | Vorinostat | HDAC | Misc | 0.88364 | -0.4902 | 0.3827 | 0.1366 | 1.5106 | 1.4957 | 0.98509 |
| CAMA-1 | Luminespib | HSP90 | Misc | 0.0088457 | -0.0698 | 0.5359 | 0.0808 | 5.0000 | 0.0090456 | 0.99836 |
| CAMA-1 | A-1210477 | Mcl-1 | Misc | Inf | 0.8758 | 0.0026 | 0.0051 | 0.0000 | Inf | 0.45696 |
| CAMA-1 | Olaparib | PARP | Misc | 14.8517 | 0.6788 | 0.0527 | -0.0008 | 1.4312 | 31.9803 | 0.84248 |
| CAMA-1 | Bleomycin | Radiation | Misc | 1.6866 | -0.0365 | 0.2741 | 0.0341 | 0.6542 | 9.0438 | 0.951 |
| CAMA-1 | Ipatasertib | AKT | PI3K/mTOR | 0.34089 | -0.2361 | 0.4116 | 0.0837 | 0.7950 | 0.66403 | 0.98884 |
| CAMA-1 | Alpelisib | PI3Ka | PI3K/mTOR | Inf | 0.9788 | 0.0106 | 0.0056 | 0.0000 | Inf | -0.0228 |
| CAMA-1 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 1.7729 | -0.1525 | 0.2454 | 0.0541 | 0.7933 | 7.0816 | 0.98719 |
| CAMA-1 | TGX221 | PI3Kb | PI3K/mTOR | 42.7345 | 0.8500 | 0.0067 | 0.0034 | 0.9968 | 118.889 | 0.79474 |
| CAMA-1 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0091746 | -0.1470 | 0.5071 | 0.0717 | 1.1560 | 0.0098166 | 0.97482 |
| CAMA-1 | Everolimus | mTOR1 | PI3K/mTOR | -Inf | 0.1642 | 0.7666 | 0.0258 | 0.1000 | 1.9385e-07 | 0.61758 |
| CAMA-1 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.0096119 | -0.0962 | 0.6396 | 0.0808 | 1.3963 | 0.0099563 | 0.98744 |
| CAMA-1 | PF-4708671 | p70S6K | PI3K/mTOR | 15.3455 | 0.6555 | 0.0582 | 0.0027 | 1.1133 | 41.0889 | 0.78738 |
| CAMA-1 | Buparlisib | pan PI3K | PI3K/mTOR | 1.0052 | -0.4226 | 0.3535 | 0.1148 | 2.4879 | 1.2949 | 0.98951 |
| CAMA-1 | Pictilisib | pan PI3K | PI3K/mTOR | 1.5489 | -0.2370 | 0.2620 | 0.0557 | 0.8407 | 5.7216 | 0.99225 |
| CAMA-1 | Ceritinib | ALK | RTK | 1.797 | -0.6988 | 0.2366 | 0.0972 | 1.5849 | 3.5941 | 0.99647 |